Spots Global Cancer Trial Database for XELOX for Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: XELOX for Metastatic Breast Cancer
Official Title: A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer
Study ID: NCT00204776
Conditions
Interventions
Study Description
Brief Summary: Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Wisconsin, Madison, Wisconsin, United States
Contact Details
Name: Sherry Morgan-Meadows
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
